Speakers
Adam Gilbert
Executive Director, External Innovation Accelerator
Pfizer
Akihiro Furukawa
Director, Research & Technology Search & Evaluation
Daiichi Sankyo
Alexandra Joseph
Chief Scientific Officer
Photys Therapeutics
Andrew Combs
Chief Chemistry Officer
Prelude Therapeutics
Anita Bellail
Chief Operating Officer & Chief Scientific Officer
HB Therapeutics
Ann Rowley
Director Targeted Protein Degradation
Merck
Anna Rivkin
Chief Business Officer
Foghorn Therapeutics
Arnout Schepers
Chief Executive Officer
TenAces Biosciences
Brent Meadows
Chief Business Officer
Polymed Biopharmaceuticals
Bret Williams
Senior Vice President of Research
Magnet Biomedicine
Carla Bauer
Director, Oncology Search and Evaluation, Business Development
Merck
Christopher Guenard
Vice President Corporate Development
Photys Therapeutics
Danette Daniels
Vice President, Protein Degrader Platform
Foghorn Therapeutics
David Fang
Senior Director, Search & Evaluation
AstraZeneca
David Younger
Co-founder & Chief Executive Officer
A-Alpha Bio
Effie Tozzo
Chief Scientific Officer
Avilar Therapeutics
Elena Diez
Senior Director External Innovation
Janssen
Giovanni Spagnolli
Co-founder & Chief Technology Officer
Sibylla Biotech
Gwenn Hansen
Chief Scientific Officer
Nurix Therapeutics
Miki Hayano
Business Development
Monte Rosa Therapeutics
Minoru Kameda
Scouting & Transaction Lead Business Development
Astellas Pharma
Philippe Nantermet
Executive Director Enabling Technologies, Business Development & Licensing
Merck
Reza Mazhari
Chief Business Officer
TRIANA Biomedicines
Rick Ewing
Vice President, Head of Chemistry
Rapafusyn Pharmaceuticals
Seth Goldblum
Senior Vice President - Corporate Development
Cullgen
Xiaodong Zhang
Director of Search & Evaluation, Oncology & Hematology
Novartis
Yue Xiong
Chief Scientific Officer
Cullgen